Purple Biotech Ltd. American Depositary Shares
Compare this stock
PPBT Stock Report Card
$
15%
Performance
Score:
10/100
PPBT returned -52.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
11/100
PPBT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
Score:
10/100
PPBT has missed earnings 7 times in the last 20 quarters.
Profit
Score:
11/100
Out of the last 20 quarters, PPBT has had 1 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
48/100
PPBT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
Purple Biotech Ltd. American Depositary Shares Summary
Nasdaq / PPBT
Healthcare
Biotechnology
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
PPBT scored poorly on our reportcard. Here are some similar companies and how they performed.
